{"id":52362,"date":"2021-06-22T15:33:00","date_gmt":"2021-06-22T15:33:00","guid":{"rendered":"https:\/\/www.verificat.cat\/why-are-some-places-giving-one-dose-instead-of-two-to-those-who-have-passed-covid-19\/"},"modified":"2023-11-01T08:09:34","modified_gmt":"2023-11-01T08:09:34","slug":"why-are-some-places-giving-one-dose-instead-of-two-to-those-who-have-passed-covid-19","status":"publish","type":"post","link":"https:\/\/www.verificat.cat\/en\/why-are-some-places-giving-one-dose-instead-of-two-to-those-who-have-passed-covid-19\/","title":{"rendered":"Why are some places giving one dose instead of two to those who have passed covid-19?"},"content":{"rendered":"<p><br \/>\n<\/p>\n<p>You are asking us why some countries are administering two injections to patients who have already passed covid-19, while in Spain this group is being vaccinated only once. Having a look at the scientific literature on the subject, the monodose strategy in those who have already passed the SARS-CoV-2 infection not only has advantages on a personal level, but is also beneficial for the rest of the population. We explain why.<\/p>\n<p>Although to date more countries <a href=\"https:\/\/www.mscbs.gob.es\/profesionales\/saludPublica\/prevPromocion\/vacunaciones\/covid19\/docs\/COVID-19_Actualizacion7_EstrategiaVacunacion.pdf\" target=\"_blank\" rel=\"noopener\">such as Spain<\/a> apply a single dose to those who have already passed SARS-CoV-2 infection and are younger than 65, the political debate is still on the table. The <a href=\"https:\/\/www.nature.com\/articles\/s41586-021-03647-4_reference.pdf\" target=\"_blank\" rel=\"noopener\">scientific literature<\/a> is increasingly clear: people who have been infected with SARS-CoV-2 have the capacity to generate antibodies in the long term. And when the body already has its own antibodies against SARS-CoV-2, a single dose confers enough protection, as explained, for example, eight researchers from the University of Maryland in <a href=\"https:\/\/www.thelancet.com\/journals\/ebiom\/article\/PIIS2352-3964(21)00194-8\/fulltext\" target=\"_blank\" rel=\"noopener\">a letter<\/a> published last 25 May in the Lancet-owned Journal EBioMedicine.&nbsp;<\/p>\n<p>In the letter, they argue that &ldquo;the emerging real-world evidence suggests that antibody responses to the first dose of vaccine in individuals with prior SARS-CoV-2 infection is equal to or higher than antibody titres found in inexperienced individuals after the second dose&quot;.&nbsp;<\/p>\n<h3>Consensus at a scientific level<\/h3>\n<p>Beyond the commentary, <strong>there is consensus at the scientific level<\/strong>: &ldquo;An <a href=\"https:\/\/www.thelancet.com\/journals\/ebiom\/article\/PIIS2352-3964(21)00194-8\/fulltext\" target=\"_blank\" rel=\"noopener\">increasing number of scientific studies<\/a> indicate that a single vaccine dose in post-infected individuals is enough to generate antibody levels equal or higher than those seen in uninfected individuals who received two doses&rdquo;, Adelaida Sarukhan, immunologist and scientific writer at ISGlobal, tells Verificat. &quot;It has also been shown that the second dose in people who have already been infected does not provide much benefit (in terms of antibody levels)&quot;, she adds.&nbsp;<\/p>\n<p>It is likely, she adds, that people who passed the infection and received a single dose of vaccine &quot;are better protected, not only because of the level of antibodies, but also because of the diversity&quot;. When someone is infected naturally, with the full virus, they generate antibodies and T-cells against different viral proteins, whereas vaccines based on the spicule protein only generate immunity specifically against the <em>Spike<\/em> protein.<\/p>\n<p>As an example of this, a recent study has shown that antibodies observed in <a href=\"https:\/\/www.nature.com\/articles\/s41586-021-03696-9\" target=\"_blank\" rel=\"noopener\">post-infected individuals<\/a> who received a single dose of vaccine <strong>are better able to neutralise new viral variants <\/strong>than antibodies in uninfected individuals who receive two doses of vaccine.<\/p>\n<p>And this, if we are talking about antibodies. If we also focus on the duration of natural versus vaccine-generated immunity, &quot;it is thought that <a href=\"https:\/\/www.nature.com\/articles\/d41586-021-01557-z\" target=\"_blank\" rel=\"noopener\">natural immunity will be quite long-lasting<\/a>,&quot; the immunologist notes, although she insists that, first, &quot;it is still too early to know which will be longer&quot; and, second, that this does not mean that it is better to be infected than vaccinated: &quot;The risks associated with infection (death, hospitalisation, persistent covid) are too great, for people of any age,&quot; she concludes. &quot;Moreover, people who have already been infected need a dose of vaccine anyway to be well protected against the new variants&rdquo;.<\/p>\n<h3>One dose, better also at the&nbsp;population level<\/h3>\n<p>Beyond the personal benefit, the scientists insist that at the population level, especially in the context of limited resources, this strategy is also beneficial: &quot;Changing the current vaccine recommendation to provide only one dose of vaccine to COVID-19 survivors would free up many urgently needed doses of vaccine&rdquo;.<\/p>\n<p>That would, for example, have a positive impact in regions where the second dose is being delayed due to lack of units: &quot;With the additional vaccines available, there would be no need,&quot; the experts in the letter conclude.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/wp-content\/uploads\/wpallimport\/files\/img\/blog\/Sistema-immunitari-EN.png\" style=\"width: 100%;height: auto\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The monodose strategy in those who have already passed the SARS-CoV-2 infection not only has advantages on a personal level, but is also beneficial for the rest of the population<\/p>\n","protected":false},"author":15,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[169],"tags":[208],"class_list":["post-52362","post","type-post","status-publish","format-standard","hentry","category-uncategorized","tag-vaccines-en","vc-legacy-post"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/posts\/52362","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/comments?post=52362"}],"version-history":[{"count":0,"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/posts\/52362\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/media?parent=52362"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/categories?post=52362"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.verificat.cat\/en\/wp-json\/wp\/v2\/tags?post=52362"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}